← The patent line

Zavegepant Hydrochloride

Sold as ZAVZPRET · given by nasal

Five to ten years until it comes off patent
7.9 yr
Until anyone may copy it
Protection runs to 2034-06-26
4
Trials running now
17 registered in total
In routine use
Furthest stage reached
already in routine clinical use
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Pfizer Inc
Approval holder
the only company permitted to sell it today
2034-06
Last patent expires
latest patent filed against this product
2028-03
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

MigraineHealthyAcute Migraine
03

Who is paying for the research

Pfizer
Company
13
Mayo Clinic
University or hospital
1
Icahn School of Medicine at Mount
University or hospital
1

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT07714369Phase 22026 · 40 people · not yet recruiting
Zavegepant Intranasal Spray for the Acute Tr

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line